[HTML][HTML] Pharmacological management of COVID-19 patients with ARDS (CARDS): a narrative review
MG Matera, P Rogliani, L Calzetta, M Cazzola - Respiratory medicine, 2020 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) is highly infectious. It has been highlighted
that if not expertly and individually managed with consideration of the vasocentric features, a …
that if not expertly and individually managed with consideration of the vasocentric features, a …
COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends
Abstract Aims The novel Coronavirus disease 2019 (COVID-19) has caused great distress
worldwide. Acute respiratory distress syndrome (ARDS) is well familiar but when it happens …
worldwide. Acute respiratory distress syndrome (ARDS) is well familiar but when it happens …
Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses—a …
EJ Ragel, LK Harris… - BMJ Open Respiratory …, 2023 - bmjopenrespres.bmj.com
Background Acute respiratory distress syndrome (ARDS) is the most severe form of lung
injury, rendering gaseous exchange insufficient, leading to respiratory failure. Despite over …
injury, rendering gaseous exchange insufficient, leading to respiratory failure. Despite over …
[HTML][HTML] A narrative review of COVID-19-related acute respiratory distress syndrome (CARDS):“typical” or “atypical” ARDS?
D Pu, X Zhai, Y Zhou, Y Xie, L Tang, L Yin… - Annals of translational …, 2022 - ncbi.nlm.nih.gov
Methods We searched for relevant literature from 1999 to 2021 published in PubMed by
using the following keywords and their combinations:“COVID-19”,“CARDS”,“ARDS”,“ …
using the following keywords and their combinations:“COVID-19”,“CARDS”,“ARDS”,“ …
[HTML][HTML] COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment–A narrative review
CA Pfortmueller, T Spinetti, RD Urman… - Best Practice & …, 2021 - Elsevier
Abstract (163 words) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
induces coronavirus-19 disease (COVID-19) and is a major health concern. Following two …
induces coronavirus-19 disease (COVID-19) and is a major health concern. Following two …
Acute respiratory distress syndrome and the use of inhaled pulmonary vasodilators in the COVID-19 era: a narrative review
A Nasrullah, S Virk, A Shah, M Jacobs, A Hamza… - Life, 2022 - mdpi.com
The Coronavirus disease (COVID-19) pandemic of 2019 has resulted in significant morbidity
and mortality, especially from severe acute respiratory distress syndrome (ARDS). As of …
and mortality, especially from severe acute respiratory distress syndrome (ARDS). As of …
COVID-19-related ARDS: key mechanistic features and treatments
J Selickman, CS Vrettou, SD Mentzelopoulos… - Journal of clinical …, 2022 - mdpi.com
Acute respiratory distress syndrome (ARDS) is a heterogeneous syndrome historically
characterized by the presence of severe hypoxemia, high-permeability pulmonary edema …
characterized by the presence of severe hypoxemia, high-permeability pulmonary edema …
[HTML][HTML] A 29-year-old male with a fatal case of COVID-19 acute respiratory distress syndrome (CARDS) and ventilator-induced lung injury (VILI)
SS Deliwala, A Ponnapalli, E Seedahmed… - The American Journal …, 2020 - ncbi.nlm.nih.gov
Objective: Unknown ethiology Background: COVID-19 patients that develop acute
respiratory distress syndrome (ARDS)“CARDS” behave differently compared to patients with …
respiratory distress syndrome (ARDS)“CARDS” behave differently compared to patients with …
Investigational pharmacological agents for the treatment of ARDS
K Aribindi, M Lim, S Lakshminrusimha… - Expert Opinion on …, 2024 - Taylor & Francis
ABSTRACT Introduction Acute Respiratory Distress Syndrome (ARDS) is a heterogeneous
form of lung injury with severe hypoxemia and bilateral infiltrates after an inciting event that …
form of lung injury with severe hypoxemia and bilateral infiltrates after an inciting event that …
Emerging pharmacological therapies for ARDS: COVID-19 and beyond
ARDS, first described in 1967, is the commonest form of acute severe hypoxemic respiratory
failure. Despite considerable advances in our knowledge regarding the pathophysiology of …
failure. Despite considerable advances in our knowledge regarding the pathophysiology of …